To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

Phase 3

• Conditions: Lupus

• Registration Number: NCT00053560
• Lead Sponsor: Genelabs Technologies

Brief Summary

The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).

Detailed Description

Not available

Study Timeline

• Study Start: 2002-12
• Study First Submitted: 2003-01-30
• Study First Submitted QC: 2003-02-01
• Study First Posted: 2003-02-03
• Study Completion: 2004-08
• Status Verified: 2004-11
• Last Update Submitted: 2007-12-26
• Last Update Posted: 2008-01-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 155

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (26)

University of Arizona; 🇺🇸 Tucson, Arizona, United States

Wallace Rheumatic Study Center; 🇺🇸 Los Angeles, California, United States

Peng T Fan, MD & Wonil Lee, MD Partnership; 🇺🇸 North Hollywood, California, United States

Lifestyles Health Science Center; 🇺🇸 Rancho Mirage, California, United States

University of California San Diego; 🇺🇸 San Diego, California, United States

East Bay Rheumatology Group; 🇺🇸 San Leandro, California, United States

Center for Rheumatology, Immunology and Arthritis; 🇺🇸 Fort Lauderdale, Florida, United States

Rheumatology Associates of Central Florida; 🇺🇸 Orlando, Florida, United States

Tampa Medical Group, P.A.; 🇺🇸 Tampa, Florida, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Scroll for more (16 remaining)